OptimizeRx (OPRX) 10-K 28 Feb 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 24, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	OptimizeRx Corporation
Trading Symbol	OPRX
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,875,435
Entity Public Float			$ 1,030,061,063
Amendment Flag	false
Entity Central Index Key	0001448431
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-38543
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	26-1265381
Entity Address, Address Line One	400 Water Street,
Entity Address, Address Line Two	Ste. 200
Entity Address, City or Town	Rochester
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48307
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	UHY LLP
Auditor Location	Sterling Heights, Michigan
Auditor Firm ID	1195
City Area Code	248
Local Phone Number	651-6568

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 84,681,770	$ 10,516,776
Accounts receivable, net	24,800,585	17,885,705
Prepaid expenses	5,630,655	4,456,611
Total Current Assets	115,113,010	32,859,092
Property and equipment, net	143,818	148,854
Other Assets
Goodwill	14,740,031	14,740,031
Technology assets, net	4,589,126	5,251,822
Patent rights, net	2,155,026	2,349,570
Right of use assets, net	328,820	445,974
Other intangible assets, net	3,902,502	4,519,552
Security deposits and other assets	12,859	12,859
Total Other Assets	25,728,364	27,319,808
TOTAL ASSETS	140,985,192	60,327,754
Current Liabilities
Accounts payable – trade	606,808	618,250
Accrued expenses	2,902,836	2,420,361
Revenue share payable	4,378,216	4,969,868
Current portion of lease liabilities	90,982	123,220
Contingent purchase price payable		1,610,813
Deferred revenue	1,389,907	285,795
Total Current Liabilities	9,368,749	10,028,307
Non-current Liabilities
Lease liabilities, net of current portion	236,726	325,533
Total Liabilities	9,605,475	10,353,840
Commitments and contingencies (See Note 14)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2021 and 2020,
Common stock, $0.001 par value, 166,666,667 shares authorized, 17,860,975 and 15,223,340 shares issued and outstanding at December 31, 2021 and 2020, respectively	17,861	15,223
Additional paid-in-capital	166,615,514	85,590,428
Accumulated deficit	(35,253,658)	(35,631,737)
Total Stockholders’ Equity	131,379,717	49,973,914
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 140,985,192	$ 60,327,754

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	166,666,667	166,666,667
Common stock, shares issued	17,860,975	15,223,340
Common stock, shares outstanding	17,860,975	15,223,340

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 61,292,598	$ 43,313,323
Cost of revenues	25,654,384	19,207,902
Gross margin	35,638,214	24,105,421
Operating Expenses
Stock-based compensation	5,491,957	3,172,840
Depreciation, amortization, and noncash lease expense	2,086,454	2,075,888
Other general and administrative expenses	27,698,703	20,992,012
Total operating expenses	35,277,114	26,240,740
Income (loss) from operations	361,100	(2,135,319)
Other income (expense)
Interest income	16,979	68,582
Change in fair value of contingent consideration		(140,390)
Total other income (expense)	16,979	(71,808)
Income (loss) before provision for income taxes	378,079	(2,207,127)
Income tax benefit
Net income (loss)	$ 378,079	$ (2,207,127)
Weighted average number of shares outstanding – basic (in Shares)	17,228,019	14,827,923
Weighted average number of shares outstanding – diluted (in Shares)	17,690,489	14,827,923
Income (loss) per share – basic (in Dollars per share)	$ 0.02	$ (0.15)
Income (loss) per share – diluted (in Dollars per share)	$ 0.02	$ (0.15)

Consolidated Statement of Stock

Consolidated Statement of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 14,601	$ 78,272,268	$ (33,424,610)	$ 44,862,259
Balance (in Shares) at Dec. 31, 2019	14,600,579
Stock-based compensation expense
Options		1,884,202		1,884,202
Restricted Stock	$ 84	838,430		838,514
Restricted Stock (in Shares)	84,746
Issuance of common stock:
For board compensation	$ 29	450,095		450,124
For board compensation (in Shares)	28,809
For stock options exercised	$ 415	2,487,979		2,488,394
For stock options exercised (in Shares)	414,705
For contingent purchase price and escrow hold back	$ 94	1,657,454		1,657,548
For contingent purchase price and escrow hold back (in Shares)	94,501
Net income for the year			(2,207,127)	(2,207,127)
Balance at Dec. 31, 2020	$ 15,223	85,590,428	(35,631,737)	49,973,914
Balance (in Shares) at Dec. 31, 2020	15,223,340
Stock-based compensation expense
Options		2,709,781		2,709,781
Restricted Stock	$ 3	2,532,088		2,532,091
Restricted Stock (in Shares)	3,333
Issuance of common stock:
For board compensation	$ 5	250,080		250,085
For board compensation (in Shares)	4,730
For stock options exercised	$ 1,106	4,863,125		4,864,231
For stock options exercised (in Shares)	1,105,822
Public offering of common shares, net of offering costs	$ 1,524	70,670,012		70,671,536
Public offering of common shares, net of offering costs (in Shares)	1,523,750
Net income for the year			378,079	378,079
Balance at Dec. 31, 2021	$ 17,861	$ 166,615,514	$ (35,253,658)	$ 131,379,717
Balance (in Shares) at Dec. 31, 2021	17,860,975

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 378,079	$ (2,207,127)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	1,965,325	1,971,083
Noncash lease expense	121,129	104,805
Increase in bad debt reserve	80,000	200,000
Stock-based compensation	5,491,957	3,172,840
Change in fair value of contingent consideration		140,390
Changes in:
Accounts receivable	(6,994,880)	(10,667,680)
Prepaid expenses and other assets	(1,174,044)	(3,517,700)
Accounts payable	(11,442)	125,255
Revenue share payable	(591,652)	3,351,430
Accrued expenses and other	482,475	1,416,884
Change in operating lease liabilities	(125,020)	(106,347)
Deferred revenue	1,104,112	(294,219)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	726,039	(6,310,386)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(100,322)	(68,041)
Acquisition of intangible assets, including intellectual property rights	(21,511)	(11,932)
Capitalized software development costs	(364,166)	(44,752)
NET CASH USED IN INVESTING ACTIVITIES	(485,999)	(124,725)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of offering costs	70,671,536
Proceeds from exercise of stock options	4,864,231	2,488,394
Payment of contingent consideration	(1,610,813)	(4,389,187)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	73,924,954	(1,900,793)
NET INCREASE (DECREASE IN) CASH AND CASH EQUIVALENTS	74,164,994	(8,335,904)
CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD	10,516,776	18,852,680
CASH AND CASH EQUIVALENTS – END OF PERIOD	84,681,770	10,516,776
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition liabilities paid in stock		$ 1,657,548

Organization and Nature of Busi

Organization and Nature of Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS OptimizeRx is a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary point-of-care network, OptimizeRx helps patients start and stay on their medications.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates. Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: OptimizeRx Corporation, a Michigan corporation, RMDY Health, Inc., a Delaware corporation, CareSpeak Communications, Inc., a New Jersey corporation, Cyberdiet, a controlled foreign corporation incorporated in Israel, and CareSpeak Communications D.O.O., a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company.” All material intercompany transactions have been eliminated. Reclassifications Certain items in the previous year financial statements have been reclassified to match the current year presentation. Foreign Currency The Company’s functional currency is the U.S. dollar, however it pays certain expenses related to its two foreign subsidiaries in the local currency, which is the sheckel for its subsidiary in Israel and the kuna for its Croatian subsidiary. All transactions are recorded at the exchange rate at the time of payment. If there is a time lag between the time of recording the liability and the time of payment, a gain or loss is recorded in the Consolidated Statement of Operations due to any fluctuations in the exchange rate. Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments, consisting of money market accounts, with an initial maturity of three months or less to be cash equivalents. Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs. The following tables present the fair values and carrying values of the Company’s financial assets and liabilities measured on a recurring basis as of December 31, 2021 and 2020 and the valuation techniques used by the Company to determine those fair values. 2021 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable $ - $ - $ - $ - $ - 2020 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable (1) $ - $ - $ 1,610,813 $ 1,610,813 $ 1,610,813 (1) The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. For 2020, the final payout had been determined and was paid in 2021. The following table provides a summary of changes in fair value of the Company’s Level 3 financial instruments for the years ended December 31, 2021 and 2020. Amount Balance December 31, 2019 $ 6,720,000 Payment of CareSpeak Communication contingent consideration (1,389,187 ) Payment of RMDY Health, Inc. contingent consideration (3,860,390 ) Increase in the value of the RMDY Health, Inc. contingent consideration 140,390 Balance December 31, 2020 1,610,813 Payment of CareSpeak Communication contingent consideration (1,610,813 ) Balance December 31, 2021 $ - Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $80,000 for the year ended December 31, 2021 and $200,000 for the year ended December 31, 2020. The allowance for doubtful accounts was $241,219 and $158,163 as of December 31, 2021 and 2020, respectively. From time to time, we may record revenue based on our revenue recognition policies described below in advance of being able to invoice the customer. Included in accounts receivable are unbilled amounts of $2,110,865 and $757,218 at December 31, 2021, and December 31, 2020, respectively. Property and Equipment Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred. Intangible Assets Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, four years for covenants not to compete, and three to four years for software and websites, all using the straight-line method. These assets are evaluated when there is a triggering event. There was no impairment of our intangible assets in either year presented. Goodwill We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change. Our analysis determined that there was no impairment of our goodwill. Revenue Recognition Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized, over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. The majority of our revenue is earned from life sciences companies, such as pharmaceutical and biotech companies, or medical device makers. A small portion of our revenue is earned from other sources, such as associations and technology companies. A break down is set forth in the table below. 2021 2020 Life Science Companies $ 59,018,033 $ 41,358,746 Other 2,274,565 1,954,577 Total Revenue $ 61,292,598 $ 43,313,323 In some instances, we license certain of our software applications in arrangements that do not include other performance obligations. In those instances, we record license revenue when the software is delivered for use to the license. In instances where our contracts included Software as a service, the revenue is recognized over the subscription period as services are delivered to the customer. In some instances, the Company also resells messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where the Company sells solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that the Company receives. There were no programs recorded on a net basis in the years presented. In instances where the Company resells these messaging solutions and has all financial risk and significant operation input and risk, the Company records the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales. Cost of Revenues The primary cost of revenue is revenue share expense. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner, or others, for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense. Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2021 and 2020 the Company had $83,312,524 and $9,936,806, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America/Merrill Lynch. Research and Development The Company expenses research and development expenses as incurred. There was no research and development expense for the years ended December 31, 2021 and 2020. Stock-based Compensation The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock awards, the fair value is based on the market value of the Company’s common stock on the date of grant. For market based restricted stock units, the fair value is estimated using a Monte Carlo simulation model. This valuation technique includes estimating the movement of stock prices and the effects of volatility, interest rates and dividends. For options, fair value is estimated using the Black-Scholes option pricing model that uses the following assumptions. Estimated volatilities are based on the historical volatility of the Company’s common stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and do not expect to pay any dividends in the future. 2021 2020 Expected dividend yield 0 % 0 % Risk free interest rate 0.19% - 0.67 % 0.16% - 1.63 % Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 67 % - 70 % 65 % - 71 % Weighted average grant date fair value $ 26.36 $ 5.49 The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate. Loss Per Common and Common Equivalent Share The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain options that were excluded from the diluted loss per common share calculation in 2020 was 820,059 related to options, and 91,667 related to restricted stock units, for a total of 911,726 because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2020. The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2021 and 2020 consisted of the following: Net Income Shares Per Share Amount Year ended December 31, 2021 Basic EPS $ 378,079 17,228,019 $ 0.02 Diluted EPS $ 378,079 17,690,489 $ 0.02 Net (Loss) Shares Per Share Amount Year ended December 31, 2020 Basic EPS $ (2,207,127 ) 14,827,923 $ (0.15 ) Diluted EPS $ (2,207,127 ) 14,827,923 $ (0.15 ) Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. Segment reporting We operate in one reportable segment. Overall, our business involves connecting life science companies to patients and providers. We have a common customer base for all of our solutions, which are primarily all communications with healthcare providers or patients on behalf of life science customers. Our customers are geographically located in the U.S although we have two technology centers located internationally. We do not prepare separate internal income statements by solutions as our focus is on selling enterprise arrangements covering multiple solutions that span the entire patient journey with a specific brand. Recently Issued Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to improve consistent application and simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. ASU 2019-12 was effective for us as of January 1, 2021 The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows. Not Yet Adopted ASU Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The Company is currently evaluating the effect of this pronouncement on its Consolidated Financial Statements, but it is not expected to have a material impact.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 – PREPAID EXPENSES Prepaid expenses consisted of the following as of December 31, 2021 and 2020: 2021 2020 Prepaid revenue share and exclusivity payments 4,266,668 3,750,000 EHR access fees 250,000 317,726 Data 168,462 29,408 Insurance 156,327 77,887 Other 789,198 281,590 Total prepaid expenses $ 5,630,655 $ 4,456,611

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT The Company owned equipment recorded at cost, which consisted of the following as of December 31, 2021 and 2020: 2021 2020 Computer equipment $ 267,917 $ 169,247 Furniture and fixtures 200,250 198,665 468,167 367,912 Less accumulated depreciation 324,349 219,058 Property and equipment, net $ 143,818 $ 148,854 Depreciation expense was $105,360 and $95,202 for the years ended December 31, 2021 and 2020, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANBIGLE ASSETS Goodwill Our goodwill is related to the acquisitions of RMDY Health, Inc. in 2019 and CareSpeak Communications in 2018. Goodwill is generally not amortizable for tax purposes and is not amortizable for financial statement purposes. Intangible Assets Intangible assets included on the consolidated balance sheets consist of the following: December 31, 2021 Gross Accumulated Net Weighted Patent rights $ 3,362,898 $ 1,207,872 2,155,026 9.6 Technology Assets $ 8,548,930 $ 3,959,804 4,589,126 4.9 Other intangible assets Tradename $ 3,586,000 $ 537,900 3,084,100 12.7 Non-compete agreements 1,093,000 899,635 193,365 0.6 Customer relationships 923,000 261,963 661,037 8.4 Total other 5,602,000 1,699,498 3,902,502 Total Intangibles $ 17,513,828 $ 6,867,174 10,646,654 December 31, 2020 Gross Accumulated Net Weighted Patent rights $ 3,341,388 $ 991,818 2,349,570 11.5 Technology Assets $ 8,184,765 $ 2,932,943 5,251,822 7.7 Other intangible assets Tradename $ 3,586,000 $ 298,833 3,287,167 13.7 Non-compete agreements 1,093,000 611,885 481,115 1.6 Customer relationships 923,000 171,730 751,270 9.8 Total other 5,602,000 1,082,448 4,519,552 Total Intangibles $ 17,128,153 $ 5,007,209 12,120,944 Intangibles are being amortized on a straight-line basis over the following estimated useful lives. Patents 15 – 17 years Tradenames 15 years Non-compete agreements 2 – 4 years Customer relationships 8 – 15 years Technology assets 3 – 10 years The Company recorded amortization expense of $1,859,965 and $1,875,882 in the years ended December 31, 2021 and 2020, respectively. Expected future amortization expenses of the intangibles assets as of December 31, 2021 is as follows: Year ended December 31, 2022 $ 1,532,756 2023 1,203,639 2024 1,203,639 2025 1,131,058 2026 1,009,499 Thereafter 4,566,063 Total $ 10,646,654

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
DEFERRED REVENUE	NOTE 6 – DEFERRED REVENUE The Company has several signed contracts with customers for the distribution of financial messaging, or other services, which include payment in advance. The payments are not recorded as revenue until the revenue is earned under its revenue recognition policy discussed in Note 2. Deferred revenue was $1,389,908 and $285,795 as of December 31, 2021 and 2020, respectively. These contracts are all short term in nature and all revenue is expected to be recognized within 12 months, or less. Following is a summary of activity in the deferred revenue account for the year ended December 31, 2021. Balance January 1, 2021 $ 285,795 Revenue recognized (18,006,973 ) Amount collected 19,111,086 Balance December 31, 2021 $ 1,389,908 Following is a summary of activity in the deferred revenue account for the year ended December 31, 2020. Balance January 1, 2020 $ 580,014 Revenue recognized (16,260,166 ) Amount collected 15,680,152 Balance December 31, 2020 $ 285,795

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 7 – RELATED PARTY TRANSACTIONS During the year ended December 31, 2010, the Company acquired the technical contributions and assignment of all exclusive rights to and for a key patent in process at the time from a former CEO in exchange for a total payment in shares of common stock and options valued at $930,000 at the time of the acquisition and recorded the patent at that cost. That patent remains in Patents on the consolidated balance sheet as of December 31, 2021. Jim Lang, one of our Board Members, is the CEO of Eversana, a leading global provider of services to the life sciences industry. Eversana is similar to other customers we generate revenue from, such as agencies or resellers. During the year ended December 31, 2021, we have recognized $218,333 in revenue from contracts engaged with Eversana. No revenues were recognized in 2020 related to contracts with Eversana. These contracts were sourced by Eversana on behalf of life science customers of theirs. The contracts are at market rates and were generated in the normal course of business.

Contingent Purchase Price

Contingent Purchase Price	12 Months Ended
	Dec. 31, 2021
Loss Contingency [Abstract]
CONTINGENT PURCHASE PRICE	NOTE 8 – CONTINGENT PURCHASE PRICE Our purchase of CareSpeak Communications contained a contingent element that would be paid only if the Company achieved certain patient engagement revenues in 2019 and 2020. The total contingent payment could have been up to $3.0 million. The target patient engagement revenues were achieved in both 2019 and in 2020. The calculated fair value of the contingent payment was $3,000,000 at December 31, 2019 and $1,610,813 at December 31, 2020. The final required payment was made in 2021. Our purchase of RMDY Health, Inc. also contained a contingent element that would be paid only if the Company achieves certain revenues in 2020 and 2021 related to the RMDY business. The total contingent payment could have been up to $30.0 million. The minimum payment was $1.0 million in each of the two years. The calculated fair value of the contingent payment was $3,720,000 at December 31, 2019. We determined the fair value of the Contingent Purchase Price Payable at December 31, 2019 using a Geometric-Brownian motion analysis of the expected revenue and resulting earnout payment using inputs that include the spot price, a risk free rate of return of 1.4%, a term of 2 years, and volatility of 35%. During 2020, we reached agreement with the former shareholders of RMDY to fix the liability at $3.75 million, payable in a combination of cash and stock. Because of the change in the share price between the date of agreement and the date of payment, the amount recorded for the stock amount varied from the agreed amount. The liability was paid in full during 2020 and was paid with a $3.0 million cash payment and the remainder in shares of common stock. There was no contingent purchase price payable at December 31, 2021. The total fair value of contingent purchase price payable at December 31, 2020 is as follows. Current Long-Term Total CareSpeak Communications, Inc. $ 1,610,813 - $ 1,610,813 RMDY Health - - - Total $ 1,610,813 $ - $ 1,610,813

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 – STOCKHOLDERS’ EQUITY Preferred Stock The Company has 10,000,000 shares of preferred stock, $.001 par value per share, authorized as of December 31, 2021. No shares were issued or outstanding in either 2020 or 2021. Common Stock The Company had 166,666,667 shares of common stock, $.001 par value per share, authorized as of December 31, 2021. There were 17,860,975 and 15,223,340 shares of common stock issued and outstanding at December 31, 2021 and 2020, respectively. During the quarter ended March 31, 2021, in an underwritten primary offering, we issued 1,523,750 shares of our common stock for gross proceeds of $75,425,625. In connection with this transaction, we incurred equity issuance costs of $4,754,089 related to payments to the underwriter, advisors and legal fees associated with the transaction, resulting in net proceeds to the Company of $70,671,536. The Company had a Director Compensation plan covering its independent non-employee Directors that was in effect through June 30, 2021. A total of 4,730 and 28,809 shares were granted and issued in the years ended December 31, 2021 and 2020, respectively, in connection with this compensation plan. These shares were valued at $250,085 and $450,124, respectively. The plan was changed to grant restricted stock units under the Company’s 2021 Equity compensation plan and those grants are reflected in the information in Note 10. We issued 1,105,822 shares of common stock and received proceeds of $4,864,231 in 2021 in connection with the exercise of options. We also issued 414,705 shares of common stock and received proceeds of $2,488,394 in 2020 in connection with the exercise of options. We issued 3,333 shares of common stock in 2021 and 84,746 shares of common in stock in 2020 in connection with the vesting of restricted stock units and discussed in greater detail in Note 10, Stock Compensation.

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK COMPENSATION	NOTE 10 – STOCK COMPENSATION The Company sponsors two stock-based incentive compensation plans. The first plan is known as the 2013 Incentive Plan (the “2013 Plan”) and was established by the Board of Directors of the Company in June 2013. The 2013 Plan, as amended, authorized the issuance of 3,000,000 shares of Company common stock. The amended plan was approved by shareholders. A total of 671,011 shares of common stock underlying options and 145,550 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2021. In connection with the adoption of a new plan in 2021, the Company froze the 2013 Plan. At December 31, 2021, there were no shares available for grant under the 2013 Plan. In 2021, the Company adopted a new plan known as the 2021 Equity Incentive Plan (“2021 Plan”). The plan was established by the Board of Directors and approved by shareholders in August 2021. A total of 2,500,000 shares are authorized for issuance under the 2021 Plan. A total of 112,536 shares of common stock underlying options and 254,188 shares of common stock underlying restricted stock unit awards were outstanding at December 31, 2021. At December 31, 2021, 2,133,276 shares were available for grant under the 2021 Plan. The 2021 Plan allows the Company to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock-based awards. Incentive stock options may only be granted to persons who are regular full-time employees of the Company at the date of the grant of the option. Non-qualified options may be granted to any person, including, but not limited to, directors, officers, employees and consultants, who the Company’s Board or Compensation Committee determines. The exercise price of options granted under the 2021 Plan must be equal to at least 100% of the fair market value of our common stock as of the date of the grant of the option. Options granted under the 2021 Plan are exercisable as determined by the Compensation Committee and specified in the applicable award agreement. In no event will an option be exercisable after ten years from the date of grant. The compensation cost that has been charged against income related to options for the years ended December 31, 2021 and 2020, was $2,709,781 and $1,884,202, respectively. No income tax benefit was recognized in the consolidated statements of income and no compensation was capitalized in any of the years presented. The Company had the following option activity during the year ended December 31, 2021 and 2020: Number of Options Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic Outstanding at January 1, 2020 1,624,221 $ 6.27 Granted 467,549 $ 11.39 Exercised (420,586 ) $ 6.45 Expired or forfeited (125,666 ) $ 13.09 Outstanding at December 31, 2020 1,545,518 $ 7.31 2.3 $ 36,862,947 Granted 424,588 $ 54.34 Exercised (1,137,065 ) $ 7.33 Expired or forfeited (49,494 ) $ 24.57 Outstanding, December 31, 2021 783,547 $ 34.17 3.4 $ 23,368,961 Exercisable, December 31, 2021 197,271 $ 10.87 2.1 $ 10,109,168 The table below reflects information for the total options outstanding at December 31, 2021 Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $2.46 to $10.00 127,005 1.1 $ 4.05 $10,00 to $20.00 166,945 2.8 $ 12.51 $20.00 to $40.00 180,561 3.9 $ 30.52 $40.00 to $60.00 196,500 4.3 $ 51.88 $60.00 to $96.70 112,536 4.7 $ 75.19 Total 783,547 3.4 $ 34.17 The table below reflects information for the vested options outstanding at December 31, 2021. Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $2.46 to $10.00 78,669 0.9 $ 3.76 $10,00 to $20.00 89,938 2.5 $ 13.36 $20.00 to $40.00 28,664 3.9 $ 22.52 $40.00 to $60.00 - - - $60.00 to $96.70 - - - Total 197,271 2.1 $ 10.87 A summary of the status of the Company’s nonvested options as of December 31, 2021, and changes during the year ended December 31, 2021, is presented below. Nonvested Options Options Weighted-Average Exercise Price Nonvested at January 1, 2021 331,006 $ 12.44 Granted 424,588 54.34 Vested (119,823 ) 11.23 Forfeited (49,495 ) 24.57 Nonvested at December 31, 2021 586,276 $ 42.01 There is $9,685,867 of expense remaining to be recognized over a period of approximately 2.4 years related to options outstanding at December 31, 2021. The Company had the following restricted stock unit (“RSU”) activity during the years ended December 31, 2021 and 2020: Number of RSUs Grant date fair value Weighted average remaining contractual life (years) Outstanding at January 1, 2020 90,000 $ 10.43 Granted 94,746 $ 8.98 Shares issued (84,746 ) $ 7.54 Outstanding at December 31, 2020 100,000 $ 11.51 2.4 Granted 303,556 $ 66.30 Forfeited (485 ) $ 61.82 Shares issued (3,333 ) $ 21.20 Outstanding at December 31, 2021 399,738 $ 52.99 3.3 The Company granted restricted stock units of 303,556 and 94,746 units in 2021 and 2020, respectively, and valued at $20,125,861 and $850,985, respectively. These restricted stock units vest over a period of 1.6 to 5 years. The Company recognized expense of $2,532,091 and $838,514 in 2021 and 2020, respectively, related to these restricted stock units. A total of $18,389,797 remains to be recognized at December 31, 2021 over a period of 3.0 years. Of the restricted stock units issued in 2021, 182,938 are market-based awards that vest if the Company’s stock price hits certain price targets and maintains that price for 30 days. A total of 60,191, 60,191, and 62,016 units vest if the stock price hits $98.87, $131.82, $164.78, respectively. As described in Note 2, these market-based restricted stock units were valued using a Monte Carlo simulation model, with expected vesting in 1.6, 2.25, and 2.71 years, respectively, for the three price targets.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
LEASES	NOTE 11 – LEASES In February 2016, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance on leases. The accounting standard, effective January 1, 2019, requires virtually all leases to be recognized on the balance sheet. Under the guidance, we have elected not to separate lease and non-lease components in recognition of the lease-related assets and liabilities, as well as the related lease expense. We have operating leases with terms greater than 12 months for office space in three multitenant facilities, which are recorded as assets and liabilities. The lease on our headquarters space in Rochester, Michigan expires November 30, 2023, with a renewal option through 2025, with monthly rent payable at rates ranging from $6,384 to $6,688. We have assumed renewal of the lease. We also have a lease on office space in Cranbury, New Jersey, which expired in January 2022 with a monthly payment of $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2024. Lease-related assets, or right-of-use assets, are recognized at the lease commencement date at amounts equal to the respective lease liabilities, adjusted for prepaid lease payments, initial direct costs, and lease incentives received. Lease-related liabilities are recognized at the present value of the remaining contractual fixed lease payments, discounted using our incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. For the years ended December 31, 2021 and 2020, the Company’s lease cost consisted of the following components, each of which is included in operating expenses within the Company’s consolidated statements of operations: 2021 2020 Operating lease cost $ 132,305 $ 119,954 Short-term lease cost (1) 52,375 130,216 Total lease cost $ 184,680 $ 250,170 (1) Short-term lease cost includes any lease with a term of less than 12 months. The table below presents the future minimum lease payments to be made under operating leases as of December 31, 2021: For the year ending December 31, 2022 103,418 2023 100,260 2024 80,550 2025 70,224 Total 354,452 Less: present value discount 26,744 Total lease liabilities $ 327,708 The weighted average remaining lease term for operating leases is 3.6 years and the weighted average discount rate used in calculating the operating lease asset and liability is 4.5%. Cash paid for amounts included in the measurement of lease liabilities was $124,919. For the year ended December 31, 2021, payments on lease obligations were $142,284 and amortization on the right of use assets was $121,129. For the year ended December 31, 2020, payments on lease obligations were $138,019 and amortization on the right of use assets was $104,805.

Major Customers and Vendors

Major Customers and Vendors	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS AND VENDORS	NOTE 12 – MAJOR CUSTOMERS AND VENDORS The Company had the following customers that accounted for 10% or greater of revenue in either 2021 or 2020. No other customers accounted for more than 10% of revenue in either year presented. 2021 2020 $ % $ % Customer A 14,268,819 23.0 5,037,888 11.6 Customer B 5,206,305 8.5 4,824,454 11.1 Customer C 3,157,075 5.2 5,469,126 12.1 Our accounts receivable included 2 agencies that represented multiple customers that individually made up more than 10% of our accounts receivable at December 31, 2021 in the percentages of 33.5% and 12.2%. As of December 31, 2020, our accounts receivable included 4 entities, including agencies that represented multiple customers that individually made up more than 10% of our accounts receivable in the percentages of 19.7%, 16.2%, 15.8% and 14.4%. The Company generates its revenues through its EHR and ePrescribe partners. It had two key partners and/or vendors through which 10% or greater of its revenue was generated in either 2021 or 2020 as set forth below. The amounts in the table below reflect the amount of revenue generated through those partners. 2021 2020 $ % $ % Partner A 33,041,503 53.9 22,813,574 52.7 Partner B 9,554,266 15.6 7,092,477 16.4

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES As of December 31, 2021, the Company had net operating loss carry-forwards for federal income tax purposes of approximately $26.4 million, consisting of pre-2018 losses in the amount of approximately $13.2 million that expire from 2021 through 2037, and post-2017 losses in the amount of approximately $13.2 million that will never expire. These net operating losses are available to offset future taxable income. The Company was formed in 2006 as a limited liability company and changed to a corporation in 2007. Activity prior to incorporation is not reflected in the Company’s corporate tax returns. In the future, the cumulative net operating loss carry-forward for income tax purposes may differ from the cumulative financial statement loss due to timing differences between book and tax reporting. The provision for Federal income tax consists of the following for the years ended December 31, 2021 and 2020: 2021 2020 Federal income tax benefit (expense) attributable to: Current operations $ (79,000 ) $ 463,000 State tax effect, net of federal benefit 582,000 - State rate change 397,000 - Change in fair value of contingent consideration - (29,000 ) Option exercise benefits, net of Section 162M limitations 2,171,000 207,000 Other permanent items (9,000 ) (7,000 ) Other adjustments (30,000 ) 104,000 NOLs expiring (26,000 ) (209,000 ) Valuation allowance (3,006,000 ) (529,000 ) Net provision for federal income tax $ - $ - 2021 2020 Current tax benefit (expense) - Federal $ - $ - Deferred tax benefit (expense) - Federal - - Adjustment of valuation allowance from business combination - - Total tax benefit (expense) on income $ - $ - The cumulative tax effect of significant items comprising our net deferred tax amount at the expected rate of 21% is as follows as of December 31, 2021 and 2020: 2021 2020 Deferred tax asset attributable to: Net operating loss carryover $ 6,887,000 $ 4,057,000 Stock compensation 809,000 353,000 Operating lease liability 88,000 94,000 Fixed Assets 13,000 - Other 85,000 44,000 Deferred tax asset $ 7,882,000 $ 4,548,000 Deferred tax liabilities attributable to: Intangibles $ (2,490,000 ) $ (2,181,000 ) Operating lease right of use assets (88,000 ) (94,000 ) Other (41,000 ) (16,000 ) Deferred tax liability $ (2,619,000 ) $ (2,291,000 ) Net deferred tax asset $ 5,263,000 2,257,000 Valuation allowance (5,263,000 ) (2,257,000 ) Net deferred tax asset, net of valuation allowance $ - $ - The ultimate realization of deferred tax assets is dependent upon the Company’s ability to generate sufficient taxable income during the periods in which the net operating losses expire and the temporary differences become deductible. The Company has determined that there is significant uncertainty that the results of future operations and the reversals of existing taxable temporary differences will generate sufficient taxable income to realize the deferred tax assets; therefore, a valuation allowance has been recorded. In making this determination, the Company considered historical levels of income, projections for future periods, and the significant amount of tax deductions to be generated from the future exercise of stock options. The tax years 2018 to 2021 remain open for potential audit by the Internal Revenue Service. There are no uncertain tax positions as of December 31, 2020 or December 31, 2021, and none are expected in the next 12 months. The Company’s foreign subsidiaries are cost centers that are primarily reimbursed for expenses, as a result they generate an immaterial amount of income or loss. Pretax book income (loss) is all from domestic operations. Up to four years of returns remain open for potential audit in foreign jurisdictions, however any audits for periods prior to ownership by the Company are the responsibility of the previous owners. Under certain circumstances issuance of common shares can result in an ownership change under Internal Revenue Code Section 382, which limits the Company’s ability to utilize carry-forwards from prior to the ownership change. Any such ownership change resulting from stock issuances and redemptions could limit the Company’s ability to utilize any net operating loss carry-forwards or credits generated before this change in ownership. These limitations can limit both the timing of usage of these laws, as well as the loss of the ability to use these net operating losses. It is likely that fundraising activities have resulted in such an ownership change.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 14 – COMMITMENTS AND CONTINGENT LIABILITIES Legal The Company is not involved in any legal proceedings. Revenue-share contracts The Company has contracts with various electronic health records systems and ePrescribe platforms, whereby we agree to share a portion of the revenue we generate for eCoupons distributed through their networks. These contracts grant audit rights related to the payments to our partners, and, in some cases would require us to pay for the audit if the audit determined there was an underpayment and the underpayment meets certain thresholds, such as 10%. From time to time the Company enters into arrangements with a partner to acquire minimum amounts of messaging capabilities. As of December 31, 2021, the Company had commitments for future minimum payments of $3.4 million that will be reflected in cost of revenues during the years from 2022 through 2023. Minimum payments are due in 2022 and 2023, in the amounts of $2.65 million and $0.75 million, respectively.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 15 – RETIREMENT PLAN The Company sponsors a defined contribution 401(k) profit sharing plan which was adopted in December 2015, effective in January 2016. Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll. There was expense of $343,221 and $373,027 recorded in 2021 and 2020, respectively, for the Company’s contributions to the plan.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions have been made in determining the carrying value of assets, depreciable and amortizable lives of tangible and intangible assets, the carrying value of liabilities, the valuation allowance for the deferred tax asset, the timing of revenue recognition and related revenue share expenses, and inputs used in the calculation of stock based compensation. Actual results could differ from these estimates.
Principles of Consolidation	Principles of Consolidation The financial statements reflect the consolidated results of OptimizeRx Corporation, a Nevada corporation, and its wholly owned subsidiaries: OptimizeRx Corporation, a Michigan corporation, RMDY Health, Inc., a Delaware corporation, CareSpeak Communications, Inc., a New Jersey corporation, Cyberdiet, a controlled foreign corporation incorporated in Israel, and CareSpeak Communications D.O.O., a Controlled Foreign Corporation incorporated in Croatia. Together, these companies are referred to as “OptimizeRx” and “the Company.” All material intercompany transactions have been eliminated.
Reclassifications	Reclassifications Certain items in the previous year financial statements have been reclassified to match the current year presentation.
Foreign Currency	Foreign Currency The Company’s functional currency is the U.S. dollar, however it pays certain expenses related to its two foreign subsidiaries in the local currency, which is the sheckel for its subsidiary in Israel and the kuna for its Croatian subsidiary. All transactions are recorded at the exchange rate at the time of payment. If there is a time lag between the time of recording the liability and the time of payment, a gain or loss is recorded in the Consolidated Statement of Operations due to any fluctuations in the exchange rate.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the accompanying financial statements, the Company considers all highly liquid instruments, consisting of money market accounts, with an initial maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining fair value, the disclosure requirements around fair value establish a fair value hierarchy for valuation inputs, which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1 – Inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – Inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The Company’s stock options and warrants are valued using level 3 inputs. The following tables present the fair values and carrying values of the Company’s financial assets and liabilities measured on a recurring basis as of December 31, 2021 and 2020 and the valuation techniques used by the Company to determine those fair values. 2021 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable $ - $ - $ - $ - $ - 2020 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable (1) $ - $ - $ 1,610,813 $ 1,610,813 $ 1,610,813 (1) The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. For 2020, the final payout had been determined and was paid in 2021. The following table provides a summary of changes in fair value of the Company’s Level 3 financial instruments for the years ended December 31, 2021 and 2020. Amount Balance December 31, 2019 $ 6,720,000 Payment of CareSpeak Communication contingent consideration (1,389,187 ) Payment of RMDY Health, Inc. contingent consideration (3,860,390 ) Increase in the value of the RMDY Health, Inc. contingent consideration 140,390 Balance December 31, 2020 1,610,813 Payment of CareSpeak Communication contingent consideration (1,610,813 ) Balance December 31, 2021 $ -
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Because the Company’s customers are primarily large well-capitalized companies, historically there has been very little bad debt expense. Bad debt expense was $80,000 for the year ended December 31, 2021 and $200,000 for the year ended December 31, 2020. The allowance for doubtful accounts was $241,219 and $158,163 as of December 31, 2021 and 2020, respectively. From time to time, we may record revenue based on our revenue recognition policies described below in advance of being able to invoice the customer. Included in accounts receivable are unbilled amounts of $2,110,865 and $757,218 at December 31, 2021, and December 31, 2020, respectively.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are being depreciated over their estimated useful lives of three to five years for office equipment and three years for computer equipment using the straight-line method of depreciation for book purposes. Maintenance and repair charges are expensed as incurred.
Intangible Assets	Intangible Assets Intangible assets are stated at cost. Finite-lived assets are being amortized over their estimated useful lives of fifteen to seventeen years for patents, eight years for customer relationships, fifteen years for tradenames, four years for covenants not to compete, and three to four years for software and websites, all using the straight-line method. These assets are evaluated when there is a triggering event. There was no impairment of our intangible assets in either year presented.
Goodwill	Goodwill We evaluate goodwill for impairment during our fiscal fourth quarter, or more frequently if an event occurs or circumstances change. Our analysis determined that there was no impairment of our goodwill.
Revenue Recognition	Revenue Recognition Recognition of revenue requires evidence of a contract, probable collection of proceeds, and completion of substantially all performance obligations. We use a 5-step model to recognize revenue. These steps are: identify the contract with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when or as the performance obligations are satisfied. Revenues are primarily generated from content delivery activities in which the Company delivers financial, clinical, or brand messaging through a distribution network of eprescribers and electronic health record technology providers (channel partners), directly to consumers, or from reselling services that complement the business. This content delivery for a customer is referred to as a program. Unless otherwise specified, revenue is recognized based on the selling price to customers. The Company’s contracts are generally all less than one year and the primary performance obligation is delivery of messages, or content, but the contract may contain additional services. Additional services may include program design, which is the design of the content delivery program, set up, and reporting. We consider set up and reporting services to be complimentary to the primary performance obligation and recognized through performance of the delivery of content. We consider program design and related consulting services to be performance obligations separate from the delivery of messages. As the content is distributed through the platform and network of channel partners (a transaction), these transactions are recorded, and revenue is recognized, over time as the distributions occur. Revenue for transactions can be realized based on a price per message, a price per redemption, as a flat fee occurring over a period of time, or upon completion of the program, depending on the client contract. The Company recognizes setup fees that are required for integrating client offerings and campaigns into the rule-based content delivery system and network over the life of the initial program, based either on time, or units delivered, depending upon which is most appropriate in the specific situation. Should a program be cancelled before completion, the balance of set up revenue is recognized at the time of cancellation, as set up fees are nonrefundable. Additionally, the Company also recognizes revenue for providing program performance reporting and maintenance, either by the Company directly delivering reports or by providing access to its online reporting portal that the client can utilize. This reporting revenue is recognized over time as the messages are delivered. Program design, which is the design of the content delivery program, and related consulting services are recognized as services are performed. The majority of our revenue is earned from life sciences companies, such as pharmaceutical and biotech companies, or medical device makers. A small portion of our revenue is earned from other sources, such as associations and technology companies. A break down is set forth in the table below. 2021 2020 Life Science Companies $ 59,018,033 $ 41,358,746 Other 2,274,565 1,954,577 Total Revenue $ 61,292,598 $ 43,313,323 In some instances, we license certain of our software applications in arrangements that do not include other performance obligations. In those instances, we record license revenue when the software is delivered for use to the license. In instances where our contracts included Software as a service, the revenue is recognized over the subscription period as services are delivered to the customer. In some instances, the Company also resells messaging solutions that are available through channel partners that are complementary to the core business and client base. These partner specific solutions are frequently similar to our own solutions and revenue recognition for these programs is the same as described above. In instances where the Company sells solutions on a commission basis, net revenue is recognized based on the commission-based revenue split that the Company receives. There were no programs recorded on a net basis in the years presented. In instances where the Company resells these messaging solutions and has all financial risk and significant operation input and risk, the Company records the revenue based on the gross amount sold and the amount paid to the channel partner as a cost of sales.
Cost of Revenues	Cost of RevenuesThe primary cost of revenue is revenue share expense. Based on the volume of transactions that are delivered through the channel partner network, the Company provides a revenue share to compensate the partner, or others, for their promotion of the campaign. Revenue shares are a negotiated percentage of the transaction fees and can also be specific to special considerations and campaigns.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. The Company recognizes the tax benefit from uncertain tax positions if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. It is the Company’s policy to include interest and penalties related to tax positions as a component of income tax expense.
Concentration of Credit Risks	Concentration of Credit Risks The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts; however, amounts in excess of the federally insured limit may be at risk if the bank experiences financial difficulties. As of December 31, 2021 and 2020 the Company had $83,312,524 and $9,936,806, respectively, in cash balances in excess of federally insured limits, primarily at Bank of America/Merrill Lynch.
Research and Development	Research and Development The Company expenses research and development expenses as incurred. There was no research and development expense for the years ended December 31, 2021 and 2020.
Stock-based Compensation	Stock-based Compensation The Company uses the fair value method to account for stock-based compensation. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital over the period during which services are rendered. The fair value of each award is estimated on the date of each grant. For restricted stock awards, the fair value is based on the market value of the Company’s common stock on the date of grant. For market based restricted stock units, the fair value is estimated using a Monte Carlo simulation model. This valuation technique includes estimating the movement of stock prices and the effects of volatility, interest rates and dividends. For options, fair value is estimated using the Black-Scholes option pricing model that uses the following assumptions. Estimated volatilities are based on the historical volatility of the Company’s common stock over the same period as the expected term of the options. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise behavior and to determine this term. The risk-free rate used is based on the U.S. Treasury yield curve in effect at the time of the grant using a time period equal to the expected option term. The Company has never paid dividends and do not expect to pay any dividends in the future. 2021 2020 Expected dividend yield 0 % 0 % Risk free interest rate 0.19% - 0.67 % 0.16% - 1.63 % Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 67 % - 70 % 65 % - 71 % Weighted average grant date fair value $ 26.36 $ 5.49 The Black-Scholes option valuation model and other existing models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. These option valuation models require the input of, and are highly sensitive to, subjective assumptions including the expected stock price volatility. The Company’s stock options have characteristics significantly different from those of traded options, and changes in the subjective input assumptions could materially affect the fair value estimate.
Loss Per Common and Common Equivalent Share	Loss Per Common and Common Equivalent Share The computation of basic (loss) earnings per common share is computed using the weighted average number of common shares outstanding during the year. The computation of diluted (loss) earnings per common share is based on the basic weighted average number of shares outstanding during the year plus common stock equivalents, which would arise from the exercise of options and warrants outstanding using the treasury stock method and the average market price per share during the year. The number of common shares potentially issuable upon the exercise of certain options that were excluded from the diluted loss per common share calculation in 2020 was 820,059 related to options, and 91,667 related to restricted stock units, for a total of 911,726 because they are anti-dilutive, as a result of a net loss for the year ended December 31, 2020. The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2021 and 2020 consisted of the following:
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell.
Segment reporting	Segment reporting We operate in one reportable segment. Overall, our business involves connecting life science companies to patients and providers. We have a common customer base for all of our solutions, which are primarily all communications with healthcare providers or patients on behalf of life science customers. Our customers are geographically located in the U.S although we have two technology centers located internationally. We do not prepare separate internal income statements by solutions as our focus is on selling enterprise arrangements covering multiple solutions that span the entire patient journey with a specific brand.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to improve consistent application and simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance. ASU 2019-12 was effective for us as of January 1, 2021 The adoption of this standard did not have a material effect on our financial position, results of operations, or cash flows.
Not Yet Adopted	Not Yet Adopted ASU Topic 2021-08 Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The Company is currently evaluating the effect of this pronouncement on its Consolidated Financial Statements, but it is not expected to have a material impact.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of financial assets and liabilities measured on a recurring basis	2021 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable $ - $ - $ - $ - $ - 2020 Level 1 Level 2 Level 3 Fair Value Carrying Value Liabilities Contingent Purchase Price Payable (1) $ - $ - $ 1,610,813 $ 1,610,813 $ 1,610,813
Schedule of changes in fair value of the Company’s Level 3 financial instruments	Amount Balance December 31, 2019 $ 6,720,000 Payment of CareSpeak Communication contingent consideration (1,389,187 ) Payment of RMDY Health, Inc. contingent consideration (3,860,390 ) Increase in the value of the RMDY Health, Inc. contingent consideration 140,390 Balance December 31, 2020 1,610,813 Payment of CareSpeak Communication contingent consideration (1,610,813 ) Balance December 31, 2021 $ -
Schedule of revenue is earned from life sciences companies	2021 2020 Life Science Companies $ 59,018,033 $ 41,358,746 Other 2,274,565 1,954,577 Total Revenue $ 61,292,598 $ 43,313,323
Schedule of expected dividends	2021 2020 Expected dividend yield 0 % 0 % Risk free interest rate 0.19% - 0.67 % 0.16% - 1.63 % Expected option term 3.5 years 3.5 years Turnover/forfeiture rate 0 % 0 % Expected volatility 67 % - 70 % 65 % - 71 % Weighted average grant date fair value $ 26.36 $ 5.49
Schedule of weighted average shares outstanding and the basic and diluted earnings per common share	Net Income Shares Per Share Amount Year ended December 31, 2021 Basic EPS $ 378,079 17,228,019 $ 0.02 Diluted EPS $ 378,079 17,690,489 $ 0.02 Net (Loss) Shares Per Share Amount Year ended December 31, 2020 Basic EPS $ (2,207,127 ) 14,827,923 $ (0.15 ) Diluted EPS $ (2,207,127 ) 14,827,923 $ (0.15 )

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	2021 2020 Prepaid revenue share and exclusivity payments 4,266,668 3,750,000 EHR access fees 250,000 317,726 Data 168,462 29,408 Insurance 156,327 77,887 Other 789,198 281,590 Total prepaid expenses $ 5,630,655 $ 4,456,611

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	2021 2020 Computer equipment $ 267,917 $ 169,247 Furniture and fixtures 200,250 198,665 468,167 367,912 Less accumulated depreciation 324,349 219,058 Property and equipment, net $ 143,818 $ 148,854

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets included on the consolidated balance sheet	December 31, 2021 Gross Accumulated Net Weighted Patent rights $ 3,362,898 $ 1,207,872 2,155,026 9.6 Technology Assets $ 8,548,930 $ 3,959,804 4,589,126 4.9 Other intangible assets Tradename $ 3,586,000 $ 537,900 3,084,100 12.7 Non-compete agreements 1,093,000 899,635 193,365 0.6 Customer relationships 923,000 261,963 661,037 8.4 Total other 5,602,000 1,699,498 3,902,502 Total Intangibles $ 17,513,828 $ 6,867,174 10,646,654 December 31, 2020 Gross Accumulated Net Weighted Patent rights $ 3,341,388 $ 991,818 2,349,570 11.5 Technology Assets $ 8,184,765 $ 2,932,943 5,251,822 7.7 Other intangible assets Tradename $ 3,586,000 $ 298,833 3,287,167 13.7 Non-compete agreements 1,093,000 611,885 481,115 1.6 Customer relationships 923,000 171,730 751,270 9.8 Total other 5,602,000 1,082,448 4,519,552 Total Intangibles $ 17,128,153 $ 5,007,209 12,120,944
Schedule of intangibles estimated useful lives	Patents 15 – 17 years Tradenames 15 years Non-compete agreements 2 – 4 years Customer relationships 8 – 15 years Technology assets 3 – 10 years
Schedule of future amortization expenses of intangibles assets	Year ended December 31, 2022 $ 1,532,756 2023 1,203,639 2024 1,203,639 2025 1,131,058 2026 1,009,499 Thereafter 4,566,063 Total $ 10,646,654

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block [Abstract]
Schedule of deferred revenue	Balance January 1, 2021 $ 285,795 Revenue recognized (18,006,973 ) Amount collected 19,111,086 Balance December 31, 2021 $ 1,389,908 Balance January 1, 2020 $ 580,014 Revenue recognized (16,260,166 ) Amount collected 15,680,152 Balance December 31, 2020 $ 285,795

Contingent Purchase Price (Tabl

Contingent Purchase Price (Tables)	12 Months Ended
	Dec. 31, 2021
Loss Contingency [Abstract]
Schedule of fair value of contingent purchase price payable	Current Long-Term Total CareSpeak Communications, Inc. $ 1,610,813 - $ 1,610,813 RMDY Health - - - Total $ 1,610,813 $ - $ 1,610,813

Stock Compensation (Tables)

Stock Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of restricted stock awards	Number of Options Weighted average exercise price Weighted average remaining contractual life (years) Aggregate intrinsic Outstanding at January 1, 2020 1,624,221 $ 6.27 Granted 467,549 $ 11.39 Exercised (420,586 ) $ 6.45 Expired or forfeited (125,666 ) $ 13.09 Outstanding at December 31, 2020 1,545,518 $ 7.31 2.3 $ 36,862,947 Granted 424,588 $ 54.34 Exercised (1,137,065 ) $ 7.33 Expired or forfeited (49,494 ) $ 24.57 Outstanding, December 31, 2021 783,547 $ 34.17 3.4 $ 23,368,961 Exercisable, December 31, 2021 197,271 $ 10.87 2.1 $ 10,109,168
Schedule of total options outstanding	Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $2.46 to $10.00 127,005 1.1 $ 4.05 $10,00 to $20.00 166,945 2.8 $ 12.51 $20.00 to $40.00 180,561 3.9 $ 30.52 $40.00 to $60.00 196,500 4.3 $ 51.88 $60.00 to $96.70 112,536 4.7 $ 75.19 Total 783,547 3.4 $ 34.17 Range of Exercise Prices Number of Options Weighted average remaining contractual life (years) Weighted average exercise price $2.46 to $10.00 78,669 0.9 $ 3.76 $10,00 to $20.00 89,938 2.5 $ 13.36 $20.00 to $40.00 28,664 3.9 $ 22.52 $40.00 to $60.00 - - - $60.00 to $96.70 - - - Total 197,271 2.1 $ 10.87
Schedule of nonvested shares	Nonvested Options Options Weighted-Average Exercise Price Nonvested at January 1, 2021 331,006 $ 12.44 Granted 424,588 54.34 Vested (119,823 ) 11.23 Forfeited (49,495 ) 24.57 Nonvested at December 31, 2021 586,276 $ 42.01
Schedule of restricted stock awards	Number of RSUs Grant date fair value Weighted average remaining contractual life (years) Outstanding at January 1, 2020 90,000 $ 10.43 Granted 94,746 $ 8.98 Shares issued (84,746 ) $ 7.54 Outstanding at December 31, 2020 100,000 $ 11.51 2.4 Granted 303,556 $ 66.30 Forfeited (485 ) $ 61.82 Shares issued (3,333 ) $ 21.20 Outstanding at December 31, 2021 399,738 $ 52.99 3.3

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of lease cost	2021 2020 Operating lease cost $ 132,305 $ 119,954 Short-term lease cost (1) 52,375 130,216 Total lease cost $ 184,680 $ 250,170 (1) Short-term lease cost includes any lease with a term of less than 12 months.
Schedule of future minimum lease payments	For the year ending December 31, 2022 103,418 2023 100,260 2024 80,550 2025 70,224 Total 354,452 Less: present value discount 26,744 Total lease liabilities $ 327,708

Major Customers and Vendors (Ta

Major Customers and Vendors (Tables)	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Schedule of customers accounted percentage of revenue	2021 2020 $ % $ % Customer A 14,268,819 23.0 5,037,888 11.6 Customer B 5,206,305 8.5 4,824,454 11.1 Customer C 3,157,075 5.2 5,469,126 12.1 2021 2020 $ % $ % Partner A 33,041,503 53.9 22,813,574 52.7 Partner B 9,554,266 15.6 7,092,477 16.4

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of federal income tax benefit	2021 2020 Federal income tax benefit (expense) attributable to: Current operations $ (79,000 ) $ 463,000 State tax effect, net of federal benefit 582,000 - State rate change 397,000 - Change in fair value of contingent consideration - (29,000 ) Option exercise benefits, net of Section 162M limitations 2,171,000 207,000 Other permanent items (9,000 ) (7,000 ) Other adjustments (30,000 ) 104,000 NOLs expiring (26,000 ) (209,000 ) Valuation allowance (3,006,000 ) (529,000 ) Net provision for federal income tax $ - $ - 2021 2020 Current tax benefit (expense) - Federal $ - $ - Deferred tax benefit (expense) - Federal - - Adjustment of valuation allowance from business combination - - Total tax benefit (expense) on income $ - $ -
Schedule of deferred tax assets	2021 2020 Deferred tax asset attributable to: Net operating loss carryover $ 6,887,000 $ 4,057,000 Stock compensation 809,000 353,000 Operating lease liability 88,000 94,000 Fixed Assets 13,000 - Other 85,000 44,000 Deferred tax asset $ 7,882,000 $ 4,548,000 Deferred tax liabilities attributable to: Intangibles $ (2,490,000 ) $ (2,181,000 ) Operating lease right of use assets (88,000 ) (94,000 ) Other (41,000 ) (16,000 ) Deferred tax liability $ (2,619,000 ) $ (2,291,000 ) Net deferred tax asset $ 5,263,000 2,257,000 Valuation allowance (5,263,000 ) (2,257,000 ) Net deferred tax asset, net of valuation allowance $ - $ -

Organization and Nature of Bu_2

Organization and Nature of Business (Details)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
U.S. healthcare providers, percentage	60.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Bad debt expense	$ 80,000	$ 200,000
Allowance for doubtful accounts	241,219	158,163
Unbilled amounts of accounts receivable	$ 2,110,865	757,218
Percentage of realized upon ultimate settlement	50.00%
Cash balances for insured limits	$ 83,312,524	$ 9,936,806
Diluted loss per common share (in Shares)		820,059
Restricted stock (in Shares)		911,726
Restricted Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Restricted stock (in Shares)		91,667

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured on a recurring basis - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Purchase Price Payable		$ 1,610,813	[1]
Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Purchase Price Payable
Level 2 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Purchase Price Payable
Level 3 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Purchase Price Payable		1,610,813	[1]
Fair Value [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent Purchase Price Payable		$ 1,610,813	[1]
[1]	The contingent consideration is based off achieving certain revenue milestones in each of the next two years. The Geometric-Brownian motion analysis was used to generate spot prices for use in an option pricing model. For 2020, the final payout had been determined and was paid in 2021.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of changes in fair value of the Company’s Level 3 financial instruments - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of changes in fair value of the Company’s Level 3 financial instruments [Abstract]
Balance		$ 1,610,813	$ 6,720,000
Payment of CareSpeak Communication contingent consideration	$ (1,610,813)	(1,389,187)
Payment of RMDY Health, Inc. contingent consideration		(3,860,390)
Increase in the value of the RMDY Health, Inc. contingent consideration		$ 140,390

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of revenue is earned from life sciences companies - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of revenue is earned from life sciences companies [Abstract]
Life Science Companies	$ 59,018,033	$ 41,358,746
Other	2,274,565	1,954,577
Total Revenue	$ 61,292,598	$ 43,313,323

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of expected dividends - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Expected option term	3 years 6 months	3 years 6 months
Turnover/forfeiture rate	0.00%	0.00%
Weighted average grant date fair value (in Dollars)	$ 26.36	$ 5.49
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.19%	0.16%
Expected volatility	67.00%	65.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.67%	1.63%
Expected volatility	70.00%	71.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details) - Schedule of weighted average shares outstanding and the basic and diluted earnings per common share - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of weighted average shares outstanding and the basic and diluted earnings per common share [Abstract]
Basic EPS, Net Income	$ 378,079	$ (2,207,127)
Basic EPS, Shares	17,228,019	14,827,923
Basic EPS, Per Share Amount	$ 0.02	$ (0.15)
Diluted EPS, Net Income	$ 378,079	$ (2,207,127)
Diluted EPS, Shares	17,690,489	14,827,923
Diluted EPS, Per Share Amount	$ 0.02	$ (0.15)

Prepaid Expenses (Details) - Sc

Prepaid Expenses (Details) - Schedule of prepaid expenses - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses [Abstract]
Prepaid revenue share and exclusivity payments	$ 4,266,668	$ 3,750,000
EHR access fees	250,000	317,726
Data	168,462	29,408
Insurance	156,327	77,887
Other	789,198	281,590
Total prepaid expenses	$ 5,630,655	$ 4,456,611

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 105,360	$ 95,202

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 468,167	$ 367,912
Less accumulated depreciation	324,349	219,058
Property and equipment, net	143,818	148,854
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	267,917	169,247
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Subtotal	$ 200,250	$ 198,665

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 1,859,965	$ 1,875,882

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 17,513,828	$ 17,128,153
Accumulated Amortization	6,867,174	5,007,209
Intangible assets, Net	$ 10,646,654	$ 12,120,944
Weighted Average Life Remaining
Technology Assets [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 8,548,930	$ 8,184,765
Accumulated Amortization	3,959,804	2,932,943
Intangible assets, Net	$ 4,589,126	$ 5,251,822
Weighted Average Life Remaining	4 years 10 months 24 days	7 years 8 months 12 days
Patent rights [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,362,898	$ 3,341,388
Accumulated Amortization	1,207,872	991,818
Intangible assets, Net	$ 2,155,026	$ 2,349,570
Weighted Average Life Remaining	9 years 7 months 6 days	11 years 6 months
Tradename [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 3,586,000	$ 3,586,000
Accumulated Amortization	537,900	298,833
Intangible assets, Net	$ 3,084,100	$ 3,287,167
Weighted Average Life Remaining	12 years 8 months 12 days	13 years 8 months 12 days
Non-compete agreements [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 1,093,000	$ 1,093,000
Accumulated Amortization	899,635	611,885
Intangible assets, Net	$ 193,365	$ 481,115
Weighted Average Life Remaining	7 months 6 days	1 year 7 months 6 days
Customer relationships [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 923,000	$ 923,000
Accumulated Amortization	261,963	171,730
Intangible assets, Net	$ 661,037	$ 751,270
Weighted Average Life Remaining	8 years 4 months 24 days	9 years 9 months 18 days
Other intangible assets [Member]
Intangible Assets (Details) - Schedule of intangible assets included on the consolidated balance sheet [Line Items]
Intangible assets, Gross Carrying Amount	$ 5,602,000	$ 5,602,000
Accumulated Amortization	1,699,498	1,082,448
Intangible assets, Net	$ 3,902,502	$ 4,519,552
Weighted Average Life Remaining

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of intangibles estimated useful lives	12 Months Ended
	Dec. 31, 2021
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	15 years
Minimum [Member] | Technology assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	3 years
Minimum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	15 years
Minimum [Member] | Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	2 years
Minimum [Member] | Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	8 years
Maximum [Member] | Technology assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	10 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	17 years
Maximum [Member] | Non-compete agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	4 years
Maximum [Member] | Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles amortized estimated useful lives	15 years

Intangible Assets (Details) -_3

Intangible Assets (Details) - Schedule of future amortization expenses of intangibles assets	Dec. 31, 2021USD ($)
Schedule of future amortization expenses of intangibles assets [Abstract]
2022	$ 1,532,756
2023	1,203,639
2024	1,203,639
2025	1,131,058
2026	1,009,499
Thereafter	4,566,063
Total	$ 10,646,654

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Revenue [Abstract]
Deferred revenue	$ 1,389,908	$ 285,795

Deferred Revenue (Details) - Sc

Deferred Revenue (Details) - Schedule of deferred revenue - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of deferred revenue [Abstract]
Balance beginning	$ 285,795	$ 580,014
Revenue recognized	(18,006,973)	(16,260,166)
Amount collected	19,111,086	15,680,152
Balance ending	$ 1,389,908	$ 285,795

Related Party Transactions (Det

Related Party Transactions (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Related Party Transactions [Abstract]
Common stock options	$ 930,000
Revenue from contracts	$ 218,333

Contingent Purchase Price (Deta

Contingent Purchase Price (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Contingent Purchase Price (Details) [Line Items]
Total contingent payment in cash		$ 3,000,000	$ 3,000,000
Fair value of the contingent payment		1,610,813	3,000,000
RMDY Health Shareholders [Member]
Contingent Purchase Price (Details) [Line Items]
Total contingent payment in cash	$ 30,000,000
Fair value of the contingent payment			$ 3,720,000
Minimum payment	$ 1,000,000
Risk free rate of return			1.40%
Fair value of term			2 years
Fair value of volatility			35.00%
Payment of shareholder liability		3,750,000
Payment for liability		$ 3,000,000

Contingent Purchase Price (De_2

Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable	12 Months Ended
	Dec. 31, 2021USD ($)
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total	$ 1,610,813
CareSpeak Communications, Inc. [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total	1,610,813
RMDY Health [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total
Current [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total	1,610,813
Current [Member] | CareSpeak Communications, Inc. [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total	1,610,813
Current [Member] | RMDY Health [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total
Long-Term [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total
Long-Term [Member] | CareSpeak Communications, Inc. [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total
Long-Term [Member] | RMDY Health [Member]
Contingent Purchase Price (Details) - Schedule of fair value of contingent purchase price payable [Line Items]
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in Dollars per share)		$ 0.001	$ 0.001
Common stock, shares authorized		166,666,667	166,666,667
Common stock, par value (in Dollars per share)		$ 0.001	$ 0.001
Common stock, shares issued		17,860,975	15,223,340
Common stock, shares outstanding		17,860,975	15,223,340
Shares of common stock issued	1,523,750
Gross proceeds (in Dollars)	$ 75,425,625
Issuance of common stock exercise value (in Dollars)	4,754,089
Payments to advisors and legal fees (in Dollars)	$ 70,671,536
Shares of common stock issued		1,105,822	414,705
Received proceeds (in Dollars)		$ 4,864,231	$ 2,488,394
Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized		10,000,000
Preferred stock, par value (in Dollars per share)		$ 1
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized		166,666,667
Common stock, par value (in Dollars per share)		$ 1
Common stock, shares issued		17,860,975	15,223,340
Common stock, shares outstanding		17,860,975	15,223,340
Shares of common stock issued		3,333	84,746
Director [Member]
Stockholders' Equity (Details) [Line Items]
Shares of common stock issued		4,730	28,809
Gross proceeds (in Dollars)		$ 250,085	$ 450,124

Stock Compensation (Details)

Stock Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Compensation (Details) [Line Items]
Restricted stock awards	303,556	94,746
Shares issued	112,536
Granted shares	2,133,276
Percentage of fair market value of common stock	100.00%
Compensation expense (in Dollars)	$ 2,709,781	$ 1,884,202
Expense remaining to be recognized related to unvested options (in Dollars)	9,685,867
Restricted stock units value (in Dollars)	$ 20,125,861	850,985
Vested price units description	A total of 60,191, 60,191, and 62,016 units vest if the stock price hits $98.87, $131.82, $164.78, respectively. As described in Note 2, these market-based restricted stock units were valued using a Monte Carlo simulation model, with expected vesting in 1.6, 2.25, and 2.71 years, respectively, for the three price targets.
Options Held [Member]
Stock Compensation (Details) [Line Items]
Options outstanding years	2 years 4 months 24 days
Share-based Payment Arrangement [Member]
Stock Compensation (Details) [Line Items]
Authorized shares	3,000,000
Restricted stock awards	145,550
Restricted Stock [Member]
Stock Compensation (Details) [Line Items]
Shares of common stock underlying restricted stock unit awards	254,188
Expense remaining to be recognized related to unvested options (in Dollars)	$ 18,389,797
Stock compensation recognized expense (in Dollars)	$ 2,532,091	$ 838,514
Weighted average contractual life	3 years
Restricted stock units issued	182,938
Board of Directors [Member]
Stock Compensation (Details) [Line Items]
Shares issued	2,500,000
Board of Directors [Member] | Common Stock [Member] | Share-based Payment Arrangement [Member]
Stock Compensation (Details) [Line Items]
Total shares of common stock options	671,011
Minimum [Member] | Restricted Stock [Member]
Stock Compensation (Details) [Line Items]
Vested term	1 year 7 months 6 days
Maximum [Member] | Restricted Stock [Member]
Stock Compensation (Details) [Line Items]
Vested term	5 years

Stock Compensation (Details) -

Stock Compensation (Details) - Schedule of option activity - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of option activity [Abstract]
Number of Options, Outstanding at beginning balance	1,545,518	1,624,221
Weighted average exercise price, Outstanding at beginning balance	$ 7.31	$ 6.27
Number of Options, Granted	424,588	467,549
Weighted average exercise price, Granted	$ 54.34	$ 11.39
Number of Options, Exercisable	197,271
Weighted average exercise price, Exercisable	$ 10.87
Weighted average remaining contractual life (years), Exercisable	2 years 1 month 6 days
Aggregate intrinsic value, Exercisable	$ 10,109,168
Number of Options, Exercised	(1,137,065)	(420,586)
Weighted average exercise price, Exercised	$ 7.33	$ 6.45
Number of Options, Expired or forfeited	(49,494)	(125,666)
Weighted average exercise price, Expired or forfeited	$ 24.57	$ 13.09
Number of Options, Outstanding at ending balance	783,547	1,545,518
Weighted average exercise price, Outstanding at ending balance	$ 34.17	$ 7.31
Weighted average remaining contractual life (years), Outstanding at ending balance	3 years 4 months 24 days	2 years 3 months 18 days
Aggregate intrinsic value, Outstanding at ending balance	$ 23,368,961	$ 36,862,947

Stock Compensation (Details) _2

Stock Compensation (Details) - Schedule of total and vested options outstanding	12 Months Ended
	Dec. 31, 2021$ / sharesshares
$2.46 to $10.00 [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	127,005
Weighted average remaining contractual life (years)	1 year 1 month 6 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 4.05
$2.46 to $10.00 [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	78,669
Weighted average remaining contractual life (years)	10 months 24 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 3.76
$2.46 to $10.00 [Member] | Minimum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	2.46
$2.46 to $10.00 [Member] | Minimum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	2.46
$2.46 to $10.00 [Member] | Maximum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	10
$2.46 to $10.00 [Member] | Maximum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	10
$10,00 to $20.00 [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	166,945
Weighted average remaining contractual life (years)	2 years 9 months 18 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 12.51
$10,00 to $20.00 [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	89,938
Weighted average remaining contractual life (years)	2 years 6 months
Weighted average exercise price (in Dollars per share) | $ / shares	$ 13.36
$20.00 to $40.00 [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	180,561
Weighted average remaining contractual life (years)	3 years 10 months 24 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 30.52
$20.00 to $40.00 [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	28,664
Weighted average remaining contractual life (years)	3 years 10 months 24 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 22.52
$20.00 to $40.00 [Member] | Minimum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	20
$20.00 to $40.00 [Member] | Minimum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	20
$20.00 to $40.00 [Member] | Maximum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
$20.00 to $40.00 [Member] | Maximum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
$40.00 to $60.00 [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	196,500
Weighted average remaining contractual life (years)	4 years 3 months 18 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 51.88
$40.00 to $60.00 [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options
Weighted average remaining contractual life (years)
Weighted average exercise price (in Dollars per share) | $ / shares
$40.00 to $60.00 [Member] | Minimum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
$40.00 to $60.00 [Member] | Minimum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	40
$40.00 to $60.00 [Member] | Maximum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
$40.00 to $60.00 [Member] | Maximum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
$60.00 to $96.70 [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	112,536
Weighted average remaining contractual life (years)	4 years 8 months 12 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 75.19
$60.00 to $96.70 [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options
Weighted average remaining contractual life (years)
Weighted average exercise price (in Dollars per share) | $ / shares
$60.00 to $96.70 [Member] | Minimum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
$60.00 to $96.70 [Member] | Minimum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	60
$60.00 to $96.70 [Member] | Maximum [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	96.7
$60.00 to $96.70 [Member] | Maximum [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices	96.7
Exercise Price Range [Member] | Total Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	783,547
Weighted average remaining contractual life (years)	3 years 4 months 24 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 34.17
Exercise Price Range [Member] | Vested Options Outstanding [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	197,271
Weighted average remaining contractual life (years)	2 years 1 month 6 days
Weighted average exercise price (in Dollars per share) | $ / shares	$ 10.87

Stock Compensation (Details) _3

Stock Compensation (Details) - Schedule of nonvested shares	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Schedule of nonvested shares [Abstract]
Options, Nonvested at beginning balance | shares	331,006
Weighted-Average Exercise Price, Nonvested at beginning balance | $ / shares	$ 12.44
Options, Granted | shares	424,588
Weighted-Average Exercise Price, Granted | $ / shares	$ 54.34
Options, Vested | shares	(119,823)
Weighted-Average Exercise Price, Vested | $ / shares	$ 11.23
Options, Forfeited | shares	(49,495)
Weighted-Average Exercise Price, Forfeited | $ / shares	$ 24.57
Options, Nonvested at ending balance | shares	586,276
Weighted-Average Exercise Price, Nonvested at ending balance | $ / shares	$ 42.01

Stock Compensation (Details) _4

Stock Compensation (Details) - Schedule of restricted stock awards - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of restricted stock awards [Abstract]
Number of RSUs Outstanding, beginning	100,000	90,000
Grant date fair value Outstanding, beginning		$ 10.43
Number of RSUs, Granted	303,556	94,746
Grant date fair value, Granted	$ 66.3	$ 8.98
Number of RSUs, Forfeited	(485)
Grant date fair value, Forfeited	$ 61.82
Number of RSUs, Shares issued	(3,333)	(84,746)
Grant date fair value, Shares issued	$ 21.2	$ 7.54
Number of RSUs Outstanding, ending	399,738	100,000
Grant date fair value Outstanding, ending	$ 52.99	$ 11.51
Weighted average remaining contractual life (years) Outstanding, ending	3 years 3 months 18 days	2 years 4 months 24 days

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases (Details) [Line Items]
Operating leases with terms	Nov. 30, 2023
Operating leases description	We have assumed renewal of the lease. We also have a lease on office space in Cranbury, New Jersey, which expired in January 2022 with a monthly payment of $3,158, as well as a lease of approximately $1,883 per month in Zagreb, Croatia expiring in 2024.
Weighted average remaining lease term	3 years 7 months 6 days
Weighted average discount rate	4.50%
Cash paid	$ 124,919
Payments on lease obligations	142,284	$ 138,019
Amortization on right of use assets	121,129
Amortization on the right		$ 104,805
Minimum [Member]
Leases (Details) [Line Items]
Operating leases rent payable	6,384
Maximum [Member]
Leases (Details) [Line Items]
Operating leases rent payable	$ 6,688

Leases (Details) - Schedule of

Leases (Details) - Schedule of lease cost - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Schedule of lease cost [Abstract]
Operating lease cost		$ 132,305	$ 119,954
Short-term lease cost	[1]	52,375	130,216
Total lease cost		$ 184,680	$ 250,170
[1]	Short-term lease cost includes any lease with a term of less than 12 months.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of future minimum lease payments	12 Months Ended
	Dec. 31, 2021USD ($)
Schedule of future minimum lease payments [Abstract]
2022	$ 103,418
2023	100,260
2024	80,550
2025	70,224
Total	354,452
Less: present value discount	26,744
Total lease liabilities	$ 327,708

Major Customers and Vendors (De

Major Customers and Vendors (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10.00%
Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10.00%	10.00%
Other Customer [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10.00%
One Agencies [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	33.50%
Two Agencies [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	12.20%
One Entities [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		19.70%
Two Entities [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		16.20%
Three Entities [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		15.80%
Four Entities [Member] | Accounts Receivable [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage		14.40%
Key Partners [Member]
Major Customers and Vendors (Details) [Line Items]
Concentration Risk Percentage	10.00%

Major Customers and Vendors (_2

Major Customers and Vendors (Details) - Schedule of customers accounted percentage of revenue - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Customer A [Member]
Segment Reporting Information [Line Items]
Revenue	$ 14,268,819	$ 5,037,888
Revenue percentage	23.00%	11.60%
Customer B [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,206,305	$ 4,824,454
Revenue percentage	8.50%	11.10%
Customer C [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,157,075	$ 5,469,126
Revenue percentage	5.20%	12.10%
Partner A [Member]
Segment Reporting Information [Line Items]
Revenue	$ 33,041,503	$ 22,813,574
Revenue percentage	53.90%	52.70%
Partner B [Member]
Segment Reporting Information [Line Items]
Revenue	$ 9,554,266	$ 7,092,477
Revenue percentage	15.60%	16.40%

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Operating loss expire, description	As of December 31, 2021, the Company had net operating loss carry-forwards for federal income tax purposes of approximately $26.4 million, consisting of pre-2018 losses in the amount of approximately $13.2 million that expire from 2021 through 2037, and post-2017 losses in the amount of approximately $13.2 million that will never expire.
Effective rate of tax expected	21.00%	21.00%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of federal income tax benefit - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Federal income tax benefit (expense) attributable to:
Current operations	$ (79,000)	$ 463,000
State tax effect, net of federal benefit	582,000
State rate change	397,000
Change in fair value of contingent consideration		(29,000)
Option exercise benefits, net of Section 162M limitations	2,171,000	207,000
Other permanent items	(9,000)	(7,000)
Other adjustments	(30,000)	104,000
NOLs expiring	(26,000)	(209,000)
Valuation allowance	(3,006,000)	(529,000)
Net provision for federal income tax
Current tax benefit (expense) - Federal
Deferred tax benefit (expense) - Federal
Adjustment of valuation allowance from business combination
Total tax benefit (expense) on income

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred tax asset attributable to:
Net operating loss carryover	$ 6,887,000	$ 4,057,000
Stock compensation	809,000	353,000
Operating lease liability	88,000	94,000
Fixed Assets	13,000
Other	85,000	44,000
Deferred tax asset	7,882,000	4,548,000
Deferred tax liabilities attributable to:
Intangibles	(2,490,000)	(2,181,000)
Operating lease right of use assets	(88,000)	(94,000)
Other	(41,000)	(16,000)
Deferred tax liability	(2,619,000)	(2,291,000)
Net deferred tax asset	5,263,000	2,257,000
Valuation allowance	(5,263,000)	(2,257,000)
Net deferred tax asset, net of valuation allowance

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingent Liabilities (Details) [Line Items]
Underpayment percentage			10.00%
Future minimum payments			$ 3,400
Forecast [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Minimum payments due	$ 750	$ 2,650

Retirement Plan (Details)

Retirement Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Contributions plan expense	$ 343,221	$ 373,027
Defined contribution plan, description	Under the terms of the plan, the Company matches 100% of the first 3% of payroll contributed by the employee and 50% of the next 2% of payroll contributed by the employee to a maximum of 4% of an employee’s payroll.